<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01051219</url>
  </required_header>
  <id_info>
    <org_study_id>EME-08/43/15</org_study_id>
    <secondary_id>ISRCTN</secondary_id>
    <nct_id>NCT01051219</nct_id>
  </id_info>
  <brief_title>Anti-Fibrotic Effects of Losartan In Nash Evaluation Study</brief_title>
  <acronym>FELINE</acronym>
  <official_title>A Randomised, Controlled Trial of Losartan as an Anti-fibrotic Agent in Non-alcoholic Steatohepatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Newcastle-upon-Tyne Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Newcastle University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Newcastle-upon-Tyne Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled trial to determine whether Losartan is effective at slowing
      down, halting or reversing liver fibrosis in patients with non-alcoholic steatohepatitis
      (NASH). Liver fibrosis is the accumulation of tough, fibrous scar tissue in the liver which
      occurs in patients with NASH. NASH resembles alcoholic liver disease, but occurs in people
      who drink little or no alcohol. The major feature in NASH is fat in the liver, along with
      inflammation and damage, which may lead to cirrhosis, in which the liver is permanently
      damaged and scarred and no longer able to function properly.

      Primary hypothesis:

      That losartan is superior to placebo in reversing, slowing down or halting fibrosis in
      patients with non-alcoholic fatty liver disease, after 24 months of treatment.

      Secondary hypothesis:

        1. That the safety profile of the angiotensin receptor blocker (losartan) in this patient
           population is acceptable

        2. That losartan can prevent clinical deterioration in non-alcoholic fatty liver disease

        3. That serum, radiological and histological markers of fibrosis correlate in these
           patients over a 24 month period
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome will be change in Kleiner fibrosis score, [Kleiner DE et al Hepatology 2005], based on histological fibrosis stage (as judged by two independent blinded histopathologists from liver biopsies), from pre-treatment to end-of-study</measure>
    <time_frame>trial entry, end of study (2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in radiological (fibroscan) and serological (ELF) markers of fibrosis</measure>
    <time_frame>trial entry, 48 weeks, 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in NAFLD activity score (NAS)</measure>
    <time_frame>trial entry, end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison of &quot;responder rate&quot; - placebo versus intervention</measure>
    <time_frame>trial entry, end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Losartan, daily medication</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 milligrams Losartan to be taken orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A matched placebo will be given for patients to take once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>50 milligrams to be taken orally, daily</description>
    <arm_group_label>Losartan, daily medication</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Losartan also known as Cozaar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (both males and females, aged 18+) with steatohepatitis and fibrosis (Kleiner
             F1-F3), resulting from non-alcoholic fatty liver disease.

        Exclusion Criteria:

          -  Refusal or inability (lack of capacity) to give informed consent

          -  Average alcohol ingestion &gt;21 units/week (males) or &gt;14 units/week (females)

          -  History or presence of Type 1 diabetes mellitus

          -  Haemoglobin A1C &gt;15.0

          -  Other causes of chronic liver disease or hepatic steatosis

          -  Any contra-indication to liver biopsy

          -  History of, or planned, gastrointestinal bypass surgery

          -  Hepatocellular carcinoma

          -  Previous liver transplantation

          -  Recent significant weight loss (&gt;5% total body weight within last 6 months)

          -  Electrolyte disturbance: potassium level outside the normal (local) range

          -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;10 x upper limit
             of normal (ULN) at screening

          -  Recent (within 6 months of baseline liver biopsy and screening visit) or concomitant
             use of agent known to cause hepatic steatosis (corticosteroids, amiodarone,
             methotrexate, tamoxifen, tetracycline, high dose oestrogens, valproic acid), or
             concomitant use of pioglitazone, fluconazole, rifampicin or any drug contra-indicated
             in the Losartan SmPC

          -  Introduction of metformin, glitazones, a GLP-1 agonist, Vitamin E or C, betaine,
             s-adenosyl methionine, ursodeoxycholic acid, silymarin, fibrate, pentoxifylline,
             orlistat, sibutramine or rimonabant within 3 months of baseline liver biopsy and
             screening visit

          -  Intolerance of angiotensin receptor blockers (ARBs) or presence of multiple allergic
             reactions to drugs

          -  Use of angiotensin-converting enzyme (ACE) inhibitor or ARB in previous year

          -  Hypotension (systolic &lt;100, diastolic &lt;60)

          -  Renal failure (Cr &gt;130)

          -  Participation in any clinical study of an investigational agent within 30 days or five
             half-lives of the investigational product, whichever is longer

          -  Presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, renal,
             hepatic, metabolic, haematological, neurological, psychiatric, systemic, ocular,
             gynaecologic or any acute infectious disease or signs of acute illness that, in the
             opinion of the investigator, might compromise the patient's safe participation in the
             trial

          -  Presence or history of cancer within the past 5 years with exception of adequately
             treated localized basal cell carcinoma of the skin, in situ cervical carcinoma or
             solid malignancy surgically excised in toto without recurrence for five years

          -  Women of child-bearing potential not protected by effective contraceptive method of
             birth control or surgical sterilization and/or who are unwilling or unable to be
             tested for pregnancy (Pregnancy status will be checked by serum pregnancy testing
             before initiation of study treatment and by urine pregnancy testing during the trial)

          -  Known allergy or sensitivity to losartan or its excipients (microcrystalline cellulose
             [E460]; lactose monohydrate; pregelitanized maize starch; magnesium stearate [E572];
             hydroxypropyl cellulose [E463]; hypromellose [E464])
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher P Day, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Derek Mann, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen F Stewart, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elaine McColl, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ian N Steen, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Newcastle University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <state>Devon</state>
        <zip>PL6 8DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cambridge University NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Derby Hospital</name>
      <address>
        <city>Derby</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool &amp; Broadgreen University Hospital</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guy's and St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College (St Mary's Site)</name>
      <address>
        <city>London</city>
        <zip>SW7 2AZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Foundation Trust</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Medical Centre</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.nihr.ac.uk</url>
    <description>National Institute for Health Research</description>
  </link>
  <reference>
    <citation>Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.</citation>
    <PMID>15915461</PMID>
  </reference>
  <reference>
    <citation>Newton JL, Jones DE, Henderson E, Kane L, Wilton K, Burt AD, Day CP. Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance. Gut. 2008 Jun;57(6):807-13. doi: 10.1136/gut.2007.139303. Epub 2008 Feb 12.</citation>
    <PMID>18270241</PMID>
  </reference>
  <reference>
    <citation>Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L, Colin P. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004 Mar;39(3):770-8.</citation>
    <PMID>14999696</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005 Jan;42(1):132-8.</citation>
    <PMID>15629518</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005 Jul;129(1):113-21.</citation>
    <PMID>16012941</PMID>
  </reference>
  <reference>
    <citation>Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology. 2001 Sep;121(3):685-98.</citation>
    <PMID>11522753</PMID>
  </reference>
  <reference>
    <citation>Watson MR, Wallace K, Gieling RG, Manas DM, Jaffray E, Hay RT, Mann DA, Oakley F. NF-kappaB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol. 2008 Apr;48(4):589-97. doi: 10.1016/j.jhep.2007.12.019. Epub 2008 Jan 31.</citation>
    <PMID>18279996</PMID>
  </reference>
  <reference>
    <citation>Oakley F, Meso M, Iredale JP, Green K, Marek CJ, Zhou X, May MJ, Millward-Sadler H, Wright MC, Mann DA. Inhibition of inhibitor of kappaB kinases stimulates hepatic stellate cell apoptosis and accelerated recovery from rat liver fibrosis. Gastroenterology. 2005 Jan;128(1):108-20.</citation>
    <PMID>15633128</PMID>
  </reference>
  <reference>
    <citation>Bataller R, Sancho-Bru P, Ginès P, Lora JM, Al-Garawi A, Solé M, Colmenero J, Nicolás JM, Jiménez W, Weich N, Gutiérrez-Ramos JC, Arroyo V, Rodés J. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology. 2003 Jul;125(1):117-25.</citation>
    <PMID>12851877</PMID>
  </reference>
  <reference>
    <citation>Bataller R, Gäbele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, Brenner DA, Rippe RA. Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology. 2005 May;41(5):1046-55.</citation>
    <PMID>15841463</PMID>
  </reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>October 6, 2015</last_update_submitted>
  <last_update_submitted_qc>October 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Losartan</keyword>
  <keyword>Liver fibrosis</keyword>
  <keyword>Nonalcoholic steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

